Doktor axborotnomasi 2026, №3 (124)

Тема статьи

МУЛЬТИПАРАМЕТРИЧЕСКИЙ ПОДХОД К ПРОГНОЗИРОВАНИЮ РЕЗЕКТАБЕЛЬНОСТИ ПРИ РАСПРОСТРАНЁННОМ РАКЕ ЯИЧНИКОВ: ОТ КЛАССИЧЕСКИХ ШКАЛ К ЦИФРОВЫМ И МОЛЕКУЛЯРНЫМ МОДЕЛЯМ (122-128)

Авторы

Ф. Г. Улмасов, Б. С. Эсанкулова, М. О. Эсанкулов

Учреждение

Самаркандский государственный медицинский университет, Самарканд, Узбекистан

Аннотация

Достижение полной циторедукции остаётся ключевым фактором прогноза при распространённом эпи телиальном раке яичников, однако точное дооперационное прогнозирование хирургической резектабельности по-прежнему представляет собой нерешённую клиническую задачу. В обзоре систематизированы данные ли тературы о трёх поколениях подходов к оценке резектабельности: классических клинико-лучевых шкалах и лапароскопической системе Fagotti; интегративных лабораторных и биологических моделях, основанных на опухолевых маркерах, индексах системного воспаления и характеристиках опухолевой микросреды; а также новейших цифровых инструментах — радиомике, моделях машинного обучения и молекулярном тестирова нии статуса BRCA/гомологичной рекомбинации (HRD), влияющем на выбор лечебной тактики. Отдельное внимание уделено данным рандомизированных исследований по выбору между первичной циторедуктивной операцией и неоадъювантной химиотерапией. Показано, что дальнейшее повышение точности прогнозирова ния связано с интеграцией разнородных по своей природе предикторов в единую мультипараметрическую цифровую модель, чем и обусловлена актуальность продолжающихся исследований в этом направлении.

Ключевые слова

Ключевые слова: рак яичников, резектабельность, циторедуктивная операция, индекс перитонеального кан цероматоза, радиомика, искусственный интеллект, BRCA, гомологичная рекомбинация, неоадъювантная хи миотерапия, прогнозирование. Tayanch so‘zlar: tuxumdon saratoni, rezektabellik, sitoreduktiv jarrohlik, peritoneal karsinomatoz indeksi, radiomi ka, sun’iy intellekt, BRCA, gomologik rekombinatsiya, neoad’yuvant kimyoterapiya, prognozlash. Key words: ovarian cancer, resectability, cytoreductive surgery, peritoneal carcinomatosis index, radiomics, artificial intelligence, BRCA, homologous recombination, neoadjuvant chemotherapy, prediction.

Литературы

1. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. 2. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma // Nature. — 2011. 3. Limitations of homologous recombination status testing and PARP inhibitor treatment in the current management of ovarian cancer. 4. Comprehensive genomic profiling for homologous recombination deficiency guides PARP inhibitor therapy rec ommendations in ovarian cancer. 5. BRCA Mutations, HRD Status Drive PARP Inhibitor Selection in Ovarian Cancer Maintenance // OncLive. — 2026. 6. Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer // Cancers. — 2023. 7. Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer. 8. Lu Q., Guo Y., Zhang Q. et al. A Modified Diffusion-Weighted MRI-Based Model From the Radiologist's Per spective: Improved Performance in Determining the Surgical Resectability of Advanced High-Grade Serous Ovar ian Cancer // American Journal of Obstetrics and Gynecology. — 2024. 9. Kurman R.J., Shih I.M. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded // Ameri can Journal of Pathology. 10. Radiomics and radiogenomics in ovarian cancer: a review with a focus on ultrasound applications // Cancer Imag ing. — 2025. 11. Advancing personalised care in ovarian cancer using CT and MRI radiomics // Clinical Radiology. — 2025. 12. Artificial intelligence radiomics in the diagnosis, treatment, and prognosis of gynecological cancer: a literature review // Translational Cancer Research. — 2025. 13. Predicting Response to Treatment and Survival in Advanced Ovarian Cancer Using Machine Learning and Radi omics: A Systematic Review // Cancers. — 2025. 14. Radiomics and radiogenomics: extracting more information from medical images for the diagnosis and prognostic prediction of ovarian cancer // Military Medical Research. — 2024. 15. Lin Y. et al. Artificial Intelligence in Ovarian Cancer: Current Advances and Perspectives // Medicine Advances. — 2025. 16. CD8+ T cell infiltration is associated with improved survival and negatively correlates with hypoxia in clear cell ovarian cancer // Scientific Reports. — 2023. 17. Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction. — обзорные данные, 2022. 18. Kehoe S., Hook J., Nankivell M. et al. Primary chemotherapy versus primary surgery for newly diagnosed ad vanced ovarian cancer (CHORUS) // Lancet. — 2015. 19. Vergote I., Coens C., Nankivell M. et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo ovarian cancers: pooled analysis of individual patient data from EORTC 55971 and CHORUS // Lancet Oncology. — 2018. 20. Cree I.A., White V.A., Indave B.I., Lokuhetty D. Revising the WHO classification: female genital tract tumours // Histopathology. — 2020. 21. Vergote I., Tropé C.G., Amant F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer // New England Journal of Medicine. — 2010. 22. Establishing Molecular Subgroups of CD8+ T Cell-Associated Genes in the Ovarian Cancer Tumour Microenvi ronment and Predicting the Immunotherapy Response. 23. Integrative multi-omics and machine learning approach reveals tumor microenvironment-associated prognostic biomarkers in ovarian cancer // Translational Cancer Research. — 2024. 24. Chen R., Zheng Y., Fei C. et al. Machine learning developed a CD8+ exhausted T cells signature for predicting prognosis, immune infiltration and drug sensitivity in ovarian cancer // Scientific Reports. — 2024. 25. Leveraging machine learning models to evaluate immune infiltration in the ovarian cancer microenvironment: a single-cell analysis approach // Discover Oncology. — 2025. 26. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. 27. Comparative Meta-Analysis of CA125, HE4, RMI and ROMA for Pre-operative Detection of Ovarian Carcinoma. 28. Assessment of Diagnostic Values among CA-125, RMI, HE4, and ROMA for Cancer Prediction in Women with Nonfunctional Ovarian Cysts. 29. Inflammatory Indices vs. CA 125 for the Diagnosis of Early Ovarian Cancer: Evidence from a Multicenter Pro spective Italian Cohort. 30. Comparison of the diagnostic efficacy of systemic inflammatory indicators in the early diagnosis of ovarian can cer. 31. Chi D.S., Eisenhauer E.L., Zivanovic O. et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm // Gynecologic Oncology. — 2009. 32. Differential diagnosis of benign and malignant ovarian tumors with combined tumor and systemic inflammation related markers. 33. Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours. 34. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial // British Journal of Cancer. 35. Byrom J., Widjaja E., Redman C.W. et al. Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy? // BJOG. — 2002. 36. Predictive significance of preoperative CT findings for suboptimal cytoreduction in advanced ovarian cancer: a meta-analysis. — 2018. 37. Bristow R.E., Duska L.R., Lambrou N.C. et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography // Cancer. — 2000. 38. Salani R., Axtell A., Gerardi M., Holschneider C., Bristow R.E. Limited utility of conventional criteria for predict ing unresectable disease in patients with advanced stage epithelial ovarian cancer // Gynecologic Oncology. —2008. 39. A multicenter validation of computerized tomography models as predictors of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. 40. To predict or not to predict? The dilemma of predicting the risk of suboptimal cytoreduction in ovarian cancer // Annals of Oncology. — 2011. 41. Vergote I. et al. Predicting resectability of ovarian cancer — methodological considerations. 42. du Bois A., Reuss A., Pujade-Lauraine E. et al. Role of surgical outcome as prognostic factor in advanced epitheli al ovarian cancer // Cancer. — 2009. 43. Petrillo M., Vizzielli G., Fanfani F. et al. Change of Fagotti score is associated with outcome after neoadjuvant chemotherapy for ovarian cancer. 44. Fagotti A., Ferrandina G., Fanfani F. et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma // American Journal of Obstetrics and Gynecology. — 2008. 45. Fagotti A., Ferrandina G., Fanfani F. et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study // Annals of Surgical Oncology. — 2006. 46. Suidan R.S. et al. A multicenter prospective trial evaluating preoperative CT and serum CA-125 to predict subopti mal cytoreduction. 47. Vizzielli G. et al. External validation of the modified Fagotti's laparoscopic score. 48. Prediction of Resectability of Peritoneal Disease in Ovarian Cancer Patients Using the Peritoneal Cancer Index (PCI) and Fagotti Score on MRI // Cancers. — 2026. 49. Axtell A.E., Lee M.H., Bristow R.E. et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer // Journal of Clinical On cology. 50. Kim H.J., Choi C.H., Lee Y.Y. et al. Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings // Taiwan Journal of Obstetrics and Gynecology. — 2014. 51. Georgieva S., Kornovski Y., Slavchev S. et al. The Fagotti's Score to Predict the Possibility of Optimal Cytoreduc tion in Advanced Epithelial Ovarian Cancer // Surgery, Gastroenterology and Oncology. — 2024. 52. Moore R.G., McMeekin D.S., Brown A.K. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass // Gynecologic Oncology. 53. Prat J. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum // International Journal of Gynecology & Obstetrics. — 2014. 54. Feng Z. et al. Diagnostic and prognostic value of HE4 in epithelial ovarian cancer: a meta-analysis. 55. Petrillo M., Vizzielli G., Fanfani F. et al. Definition of a dynamic laparoscopic model for the prediction of incom plete cytoreduction in advanced epithelial ovarian cancer. 56. van de Vrie R., Rutten M.J., Asseler J.D. et al. Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer // Cochrane Database of Systematic Reviews. 57. Zhang M. et al. Peritoneal Cancer Index in ovarian cancer surgical planning. 58. Rutten M.J., van de Vrie R., Bruining A. et al. Predicting surgical outcome in patients with advanced ovarian can cer using computed tomography and laparoscopy. 59. Nasser S. et al. Laparoscopic assessment of resectability in advanced ovarian cancer: a systematic review. 60. Vizzielli G., Costantini B., Tortorella L. et al. A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer. 61. Angioli R. et al. Diagnostic laparoscopy in ovarian cancer staging. 62. Suidan R.S., Ramirez P.T., Sarasohn D.M. et al. A multicenter prospective trial evaluating the ability of preopera tive computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking sur gery. 63. Torre L.A., Trabert B., DeSantis C.E. et al. Ovarian cancer statistics // CA: A Cancer Journal for Clinicians. — 2018. 64. Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA: A Cancer Journal for Clinicians. — 2024. 65. Hoskins W.J. Epidemiology of ovarian cancer. 66. Auersperg N. et al. Ovarian surface epithelium: biology, endocrinology, and pathology. 67. Doubeni C.A., Doubeni A.R., Myers A.E. Diagnosis and management of ovarian cancer // American Family Phy sician. 68. Bookman M.A. First-line chemotherapy in epithelial ovarian cancer // Clinical Obstetrics and Gynecology. 69. Dossus L., Rinaldi S., Becker S. et al. Tumor necrosis factor (TNF)-alpha, soluble TNF receptors and endometrial cancer risk: the EPIC study // International Journal of Cancer. — 2011. 70. Berek J.S. et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update // International Journal of Gyne cology & Obstetrics. 71. Elattar A., Bryant A., Winter-Roach B.A. et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer // Cochrane Database of Systematic Reviews. 72. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma // National Cancer Institute Monograph. 73. Wright A.A., Bohlke K., Armstrong D.K. et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: SGO/ASCO Clinical Practice Guideline // Journal of Clinical Oncology. 74. Colombo N., Sessa C., du Bois A. et al. ESMO–ESGO consensus conference recommendations on ovarian can cer // Annals of Oncology. 75. Siegel R.L., Giaquinto A.N., Jemal A. Cancer statistics, 2024 // CA: A Cancer Journal for Clinicians. — 2024.